Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

Friedrichsen, Martin Haljeta; Endahl, Lars; Kreiner, Frederik Flindt; Goldwater, Ronald; Kankam, Martin; Toubro, Søren; Nygård, Sune Boris

Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

Friedrichsen, Martin Haljeta; Endahl, Lars; Kreiner, Frederik Flindt; Goldwater, Ronald; Kankam, Martin; Toubro, Søren; Nygård, Sune Boris.

Friedrichsen MH; Novo Nordisk A/S, Søborg, Denmark. Electronic address: mfrc@novonordisk.com.
Endahl L; Novo Nordisk A/S, Søborg, Denmark.
Kreiner FF; Novo Nordisk A/S, Søborg, Denmark.
Goldwater R; Parexel International, Baltimore, MD, USA.
Kankam M; Altasciences Clinical Kansas, Overland Park, KS, USA.
Toubro S; Novo Nordisk A/S, Søborg, Denmark.
Nygård SB; Novo Nordisk A/S, Søborg, Denmark.

Mol Metab ; 89: 102023, 2024 Nov.

Article en En | MEDLINE | ID: mdl-39245214

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article